Tempest Therapeutics, Inc.
Income Statement
| Line Item | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 | Mar 2015 | Sep 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $197.0K | $189.0K | $146.0K | $157.0K | $75.0K | $30.0K | $15.0K | $0 |
| Cost of Revenue | $1.6M | $1.2M | $1.2M | $1.2M | $940.0K | $116.0K | $35.0K | $0 |
| Gross Profit | $-1.4M | $-1.0M | $-1.0M | $-1.0M | $-865.0K | $-86.0K | $-20.0K | $0 |
| Gross Margin | -691.4% | -552.4% | -705.5% | -637.6% | -1,153.3% | -286.7% | -133.3% | — |
| Operating Expenses | ||||||||
| Research & Development | $5.0M | $6.0M | $6.0M | $4.7M | $4.0M | $4.0M | $5.7M | $5.3M |
| SG&A Expense | $12.6M | $11.2M | $14.5M | $14.6M | $12.9M | $13.1M | $11.0M | $7.1M |
| Operating Income | $-19.0M | $-18.2M | $-21.4M | $-20.2M | $-17.8M | $-17.2M | $-16.8M | $-12.4M |
| Operating Margin | -9,626.4% | -9,651.3% | -14,684.2% | -12,891.7% | -23,696.0% | -57,246.7% | -112,086.7% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-19.2M | $-18.5M | $-21.7M | $-20.5M | $-17.9M | $-17.5M | $-17.2M | — |
| Income Tax Expense | $92.0K | $50.0K | $75.0K | $75.0K | $0 | $0 | $0 | — |
| Net Income | $-19.3M | $-18.6M | $-21.8M | $-20.6M | $-17.9M | $-17.5M | $-17.2M | $-12.9M |
| Net Margin | -9,792.4% | -9,824.3% | -14,902.7% | -13,121.7% | -23,896.0% | -58,300.0% | -114,706.7% | — |
| EPS (Basic) | $-0.02 | $-0.03 | $-0.03 | $-0.03 | $-0.03 | $-0.03 | $-0.03 | $-0.02 |
| EPS (Diluted) | $-0.02 | $-0.03 | $-0.03 | $-0.03 | $-0.03 | $-0.03 | $-0.03 | $-0.02 |
| Shares Outstanding (Basic) | 854.6M | 853.4M | 655.4M | 655.1M | 654.6M | 654.3M | 648.7M | 570.9M |
| Shares Outstanding (Diluted) | 854.6M | 853.4M | 655.4M | 655.1M | 654.6M | 654.3M | 648.7M | 570.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |